Aptamer Group raises £60,000 via Supplementary Conditional Placing

Aptamer Group

Aptamer Group plc (LON:APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced that, in addition to the Placing and Subscription announced on 24 July 2024, it has agreed to issue a further 30,000,000 New Ordinary Shares at the same issue price of 0.2p per share, raising £60,000 (before expenses), which will be for working capital purposes.

This additional sum has arisen due to a reconciliation error by the Company’s broker, Turner Pope Investments (TPI) Ltd, relating to client orders received in the Fundraising. Turner Pope noticed this matter yesterday and informed the Company and the Board has agreed to issue the Supplementary Placing Shares.

Notwithstanding the circumstances under which the proposed issue of the Supplementary Placing Shares has arisen, they will not form part of the Fundraising and will be issued as a separate tranche. Both the conditional element of the Fundraising and the Supplementary Placing Shares are subject to shareholder approval of the resolutions at the Company’s General Meeting, which is scheduled for 13 August 2024.

Subject to the passing of the resolutions at the General Meeting, admission of the Supplementary Placing Shares is expected to become effective and dealings are expected to commence at 8.00 a.m. on 14 August 2024.

Total Voting Rights

Immediately following Admission the Company will have 1,920,343,673 ordinary shares of £0.001 each in issue.

Aptamer Group does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group extends Unilever collaboration for deodorant Optimers

    Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

    Aptamer Group raises £2.0 million in share placing

    Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

    Aptamer Group raises £2m to fund growth

    Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

    Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

    Aptamer expands odour control collaboration with Unilever

    Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.

      Search

      Search